Omixon and Promovendo Form Partnership in Brazil

19/10/2017

Omixon is pleased to announce an Exclusive Distribution and Support Partnership with Promovendo, headquarted in Brazil. “Promovendo’s dedication, rich experience and extended network within the HLA-typing field will make them an excellent asset to the Omixon team. We believe the transplantation community will stand to benefit from Omixon’s world...

Automated NGS-based HLA Typing for Solid Organs at the 43rd ASHI Annual Meeting 2017

11/09/2017

Omixon announce that Holotype HLA and other Omixon products will be featured among eight posters produced by customers or collaborators at the annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in San Francisco, CA. Additionally, Omixon’s Lunchtime Symposium on Thursday will focus on NGS for solid...

Omixon at BSHI 2017 – EFI Accreditation with NGS in an NHS Lab

08/09/2017

Join Afshan Ali (Sales Manager, EMEA, Omixon), Nina Lauterbach, PhD (Field Application Scientist, Omixon) and our Guest Speaker, Dr. Brendan Clarke (HLA Lab Director, Leeds St. James’s University Hospital) for a 20 minute Lunchtime Workshop at BSHI 2017 in Leamington Spa, UK. Title: EFI Accreditation with NGS in an...

Congratulations! Promotions and Other Changes at Omixon

28/07/2017

We are happy to announce some changes in responsibility at Omixon as the following: Marcello Scala, former Director of Sales, EMEA became the Vice President Sales Operations, EMEA & Asia. As VP Sales Operations, Marcello will focus on generating new business directly with customers and through distributors, he...

New Release: HLA Twin RUO & CE 2.1.3

17/07/2017

Omixon has recently announced a major release for HLA Twin RUO & CE version 2.1.3. – the world’s most accurate, high throughput HLA genotyping software. Thanks to all your feedback and comments, we are delighted to announce a range of new features and improvements below: HML improvements New pairwise alignment...